The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrospective study which aims to explore the optimal sequence of treatment in HER2+, pertuzumab pre-treated ABC patients treated in II line with anti-HER2 agents in clinical practice. As part of the pre-clinical tasks envisioned by the STEP study, in vitro cell models of resistance were exploited to investigate molecular features associated with reduced efficacy of HER2 targeting agents at the transcript level. The aggressive behavior of resistant cell populations was measured by growth assessment in mouse models. This approach led to the identification of DARPP-32 and t-DARPP proteins as possible predictive biomarkers of efficacy of anti-HER2 agents. Biomarkers validation and the clinical goals will be reached through patients' inclusion into two independent cohorts, i.e., the prospective and retrospective cohorts, whose setup is currently ongoing.

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study / Bon, Giulia; Krasniqi, Eriseld; Porru, Manuela; D'Ambrosio, Lorenzo; Scalera, Stefano; Maugeri-Saccà, Marcello; Di Lisa, Francesca Sofia; Filomeno, Lorena; Arcuri, Teresa; Botticelli, Andrea; Santini, Daniele; Fabbri, Maria Agnese; D'Auria, Giuliana; Pulito, Claudio; Blandino, Giovanni; Marchiò, Caterina; Barba, Maddalena; Ciliberto, Gennaro; Vici, Patrizia; Pizzuti, Laura. - In: NEOPLASIA. - ISSN 1476-5586. - 45:(2023). [10.1016/j.neo.2023.100937]

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

D'Ambrosio, Lorenzo;Di Lisa, Francesca Sofia;Arcuri, Teresa;Botticelli, Andrea;Santini, Daniele;Fabbri, Maria Agnese;D'Auria, Giuliana;Pulito, Claudio;Barba, Maddalena;Pizzuti, Laura
2023

Abstract

The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrospective study which aims to explore the optimal sequence of treatment in HER2+, pertuzumab pre-treated ABC patients treated in II line with anti-HER2 agents in clinical practice. As part of the pre-clinical tasks envisioned by the STEP study, in vitro cell models of resistance were exploited to investigate molecular features associated with reduced efficacy of HER2 targeting agents at the transcript level. The aggressive behavior of resistant cell populations was measured by growth assessment in mouse models. This approach led to the identification of DARPP-32 and t-DARPP proteins as possible predictive biomarkers of efficacy of anti-HER2 agents. Biomarkers validation and the clinical goals will be reached through patients' inclusion into two independent cohorts, i.e., the prospective and retrospective cohorts, whose setup is currently ongoing.
2023
DARPP-32 and t-DARPP; HER2 positive metastatic breast cancer; PPP1R1B; Pertuzumab pretreated; Real-world evidence
01 Pubblicazione su rivista::01a Articolo in rivista
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study / Bon, Giulia; Krasniqi, Eriseld; Porru, Manuela; D'Ambrosio, Lorenzo; Scalera, Stefano; Maugeri-Saccà, Marcello; Di Lisa, Francesca Sofia; Filomeno, Lorena; Arcuri, Teresa; Botticelli, Andrea; Santini, Daniele; Fabbri, Maria Agnese; D'Auria, Giuliana; Pulito, Claudio; Blandino, Giovanni; Marchiò, Caterina; Barba, Maddalena; Ciliberto, Gennaro; Vici, Patrizia; Pizzuti, Laura. - In: NEOPLASIA. - ISSN 1476-5586. - 45:(2023). [10.1016/j.neo.2023.100937]
File allegati a questo prodotto
File Dimensione Formato  
1-s2.0-S1476558623000611-main.pdf

accesso aperto

Note: Bon_DARPP-32 and t-DARPP_2023
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 968.37 kB
Formato Adobe PDF
968.37 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1705047
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact